Moving from Bench to Bedside: A Social History of Actionability in Biomedicine
Owens, K.; Klein, A. Z.; Gonzalez-Hernandez, G.
Show abstract
Background: As medicine grows increasingly technological and scientific, biomedical researchers working to bring new knowledge to bear on clinical practice face a key question: when is a new intervention or treatment ready for clinical use? Because this is both a technical and ethical dilemma, it is crucial to examine the social history of how different approaches to this question emerge and the values or assumptions they embed. Methods: We examine the rise and proliferation of an increasingly common framework for assessing the value of new biomedical data or technology, "actionability," through a computational analysis of published scientific literature referencing this and related terms, including topic modeling and Medical Subject Headings (MeSH) term analysis of over 7000 scientific abstracts indexed in PubMed. Results: We find that actionability, as a term, began appearing more commonly in published literature in the mid-2000s, and proliferated throughout the 2010s and into the 20s. While originally used primarily in research on healthcare quality and implementation, the concept's rise in popularity is ultimately driven by uptake in the fields of clinical genetics and oncology. Conclusions: The adoption of actionability in these fields suggests that actionability as a conceptual framework may be most valuable to areas of translational medicine seeking to make sense of increasing amounts of data and technological innovation with differing levels of scientific validity and clinical utility. Recognizing this value, we also caution that actionability drives our attention primarily towards whether a test or piece of information can lead to action, not whether that action has proven benefits. As clinicians and researchers face difficult questions about how to sort through growing amounts of data to generate knowledge that can have a real impact on patient health, empirical bioethics should play a key role in analyzing the trade-offs and impacts of different approaches.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
Similar papers in this journal
- Diversity and inclusion: A hidden additional benefit of Open Data 91%
- Harnessing the Open Access Version of ChatGPT for Enhanced Clinical Opinions 90%
- Development and preliminary testing of Health Equity Across the AI Lifecycle (HEAAL): A framework for healthcare delivery organizations to mitigate the risk of AI solutions worsening health inequities 89%
Similar papers in this journal
- Transparency in the secondary use of health data: Assessing the status quo of guidance and best practices 90%
- Discrepancy review: A feasibility study of a novel peer review intervention to reduce undisclosed discrepancies between registrations and publications 88%
- A Health Economic Assessment of Relaxation of COVID-19 Controls in England 2021 88%
Similar papers in this journal
- Evidence of Unreliable Data and Poor Data Provenance in Clinical Prediction Model Research and Clinical Practice 90%
- Checklists to Detect Potential Predatory Biomedical Journals: A Systematic Review 89%
- Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis 89%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.